








CLAIMS:

1. A compound, or a pharmaceutically acceptable salt or solvate thereof, selected from:












where Pg is H, acyl,  $\text{PO}_3\text{H}_2$ , or glycosyl.




2. A compound, or a pharmaceutically acceptable salt or solvate thereof, selected from:









3. A compound, or a pharmaceutically acceptable salt or solvate thereof, selected from:






























and

where AB is an antibody.

4. The compound of claim 3, or a pharmaceutically acceptable salt or solvate thereof, wherein said antibody AB is selected from trastuzumab, trastuzumab mutants, oregovomab, edrecolomab, cetuximab, a humanized monoclonal antibody to the vitronectin receptor ( $\alpha v \beta 3$ ), alemtuzumab, anti HLA DR antibodies, 131I Lym 1, anti HLA Dr10 antibodies, anti cd33 antibodies, anti cd22 antibodies, labetuzumab, bevacizumab, ibritumomab tiuxetan, ofatumumab, panitumumab, rituximab, tositumomab, ipilimumab, and gemtuzumab.

5. A compound according to claim 3 or a pharmaceutically acceptable salt or solvate thereof

selected from



wherein X is an antibody selected from the group consisting of IL13R $\alpha$ 2-AB08-v1.0, CD33-11A1-v1417-hG1-(C), CD33-11A1-v1417-K334C-K392C-hG1-(C334+C392), and CD33-11A1-v1417-K334C-hG1-(C334).

6. A linker payload or an antibody drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, comprising a radical or a compound of claim 1.

7. An antibody drug conjugate or a pharmaceutically acceptable salt or solvate thereof, comprising a radical of a compound of claim 2.

8. A pharmaceutical composition comprising a compound of any one of claims 1-7 or a pharmaceutically acceptable salt or solvate thereof, and pharmaceutically acceptable excipient.

9. Use of a therapeutically effective amount of a compound of any one of claims 1-7 or a pharmaceutical composition of claim 8 in the manufacture of a medicament for the treatment of cancer.

10. The use of claim 9, wherein said cancer is bladder cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, kidney cancer, lung cancer, esophageal cancer, ovarian cancer, prostate cancer, pancreatic cancer, skin cancer, stomach (gastric) cancer, testicular cancer, leukemias and lymphomas.